TABLE 2.
Performances of plasma CMV PCR assay and AG in monitoring clearance of CMV viremia after initiation of preemptive therapy
| Patient no. | Time (day after transplant) of initiation of preemptive therapy | Time (day) of negative conversion after start of preemptive ganciclovir therapy
|
|
|---|---|---|---|
| Plasma PCR assay | AG | ||
| 7 | +67 | +7 | +7 |
| 11 | +47 | +14 | +7 |
| 14 | +39 | +57 | +29 |
| 21 | +59 | +20 | +13 |
| 25 | +187 | +12 | +12 |
| 26 | +447 | +7 | +7 |
| 27 | +48 | +21 | +21 |
| 30 | +60 | +23 | +13 |
| 31 | +48 | +7 | +7 |
| 36 | +34 | +20 | +11 |
| 37 | +82 | +19 | +19 |
| 38 | +37 | +22 | +22 |
| 40 | +48 | +25 | +25 |
| 42 | +55 | +45 | +5 |